[HTML][HTML] Development of a radiolabeled site-specific single-domain antibody positron emission tomography probe for monitoring PD-L1 expression in cancer
Y Chen, S Zhu, J Fu, J Lin, Y Sun, G Lv, M Xie… - Journal of …, 2022 - Elsevier
Despite advances in immunotherapy for the treatment of cancers, not all patients can benefit
from programmed cell death ligand 1 (PD-L1) immune checkpoint blockade therapy. Anti-PD …
from programmed cell death ligand 1 (PD-L1) immune checkpoint blockade therapy. Anti-PD …
SPECT/CT using [99mTc]-labeled anti-programmed death-ligand 1 (PD-L1) single-domain antibody (NM-01) to predict response to immune checkpoint inhibition in …
D Hughes, G Chand, L Meszaros, K Adamson… - 2022 - Soc Nuclear Med
2594 Introduction: Immune checkpoint inhibition with anti-programmed cell death protein 1
(PD-1) or programmed death-ligand 1 (PD-L1), alone or in combination with chemotherapy …
(PD-1) or programmed death-ligand 1 (PD-L1), alone or in combination with chemotherapy …
The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors
A Castello, L Toschi, S Rossi, E Mazziotti… - Journal of Cancer …, 2020 - Springer
Purpose This prospective study evaluated whether peripheral blood biomarkers and
metabolic parameters on F-18 fludeoxyglucose positron emission tomography/computed …
metabolic parameters on F-18 fludeoxyglucose positron emission tomography/computed …
From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
X Zhao, Y Bao, B Meng, Z Xu, S Li, X Wang… - Frontiers in …, 2022 - frontiersin.org
Developing biomarkers for accurately predicting the efficacy of immune checkpoint inhibitor
(ICI) therapies is conducive to avoiding unwanted side effects and economic burden. At the …
(ICI) therapies is conducive to avoiding unwanted side effects and economic burden. At the …
[HTML][HTML] Non-invasive PD-L1 quantification using [18F] DK222-PET imaging in cancer immunotherapy
Background Combination therapies that aim to improve the clinical efficacy to immune
checkpoint inhibitors have led to the need for non-invasive and early pharmacodynamic …
checkpoint inhibitors have led to the need for non-invasive and early pharmacodynamic …
Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic …
T Ling, L Zhang, R Peng, C Yue, L Huang - Frontiers in Immunology, 2022 - frontiersin.org
Purpose This study aimed to investigate the value of 18F-fluorodeoxyglucose positron
emission tomography/computed tomography (18F-FDG PET/CT) in predicting early …
emission tomography/computed tomography (18F-FDG PET/CT) in predicting early …
Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell …
L Zhao, J Liu, H Wang, J Shi - The British Journal of Radiology, 2021 - academic.oup.com
Objective: This study sought to investigate the association between 18F-fludeoxyglucose
(18F-FDG) uptake in positron emission tomography/CT (PET/CT) scans and different …
(18F-FDG) uptake in positron emission tomography/CT (PET/CT) scans and different …
A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect
Purpose: Efforts have been devoted to select eligible candidates for PD-1/PD-L1 immune
checkpoint blocker (ICB) immunotherapy. Here, we have a serendipitous finding of positron …
checkpoint blocker (ICB) immunotherapy. Here, we have a serendipitous finding of positron …
Expression status of PD-L1 in NSCLC correlates with disease extension
A Yamamoto, T Iwata - 2018 - Eur Respiratory Soc
Introduction: Programmed death-ligand 1 (PD-L1) is regarded as a marker of immune
tolerance and its expression is considered to be useful for immunotherapy by immune …
tolerance and its expression is considered to be useful for immunotherapy by immune …
Prognostic Significance of PD-L1 Expression and Standardized Uptake Values in the Primary Lesions of Stage IV Adenocarcinoma Lung Cancer
B Tien Cong, P Cam Phuong, PV Thai… - Frontiers in …, 2022 - frontiersin.org
Background This study evaluated the prognostic ability of 18F-fluorodeoxyglucose (18F-
FDG) positron emission tomography (PET)/computed tomography (CT) in patients with stage …
FDG) positron emission tomography (PET)/computed tomography (CT) in patients with stage …